Thr27
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr27  -  p73 (human)

Site Information
SSLEPDStyFDLPQS   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 2063601

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 ) , mutation of modification site ( 1 , 2 )
Disease tissue studied:
breast cancer ( 2 ) , lung cancer ( 2 ) , non-small cell lung cancer ( 2 ) , cancer, squamous cell carcinoma ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
CK2A2 (human) ( 1 ) , PLK1 (human) ( 2 )
Kinases, in vitro:
CK2A2 (human) ( 1 ) , PLK1 (human) ( 2 , 3 )
Treatments:
DMAT ( 1 ) , silmitasertib ( 1 )

Downstream Regulation
Effects of modification on p73:
activity, inhibited ( 2 ) , molecular association, regulation ( 2 )
Effects of modification on biological processes:
transcription, induced ( 1 ) , transcription, inhibited ( 2 )
Inhibit interaction with:
DNA ( 2 )

Disease / Diagnostics Relevance
Relevant diseases:
HNSCC ( 1 )

References 

1

Lu H, et al. (2014) CK2 Phosphorylates and Inhibits TAp73 Tumor Suppressor Function to Promote Expression of Cancer Stem Cell Genes and Phenotype in Head and Neck Cancer. Neoplasia 16, 789-800
25379016   Curated Info

2

Soond SM, et al. (2008) p73-mediated transcriptional activity is negatively regulated by polo-like kinase 1. Cell Cycle 7, 1214-23
18418051   Curated Info

3

Koida N, et al. (2008) Inhibitory role of Plk1 in the regulation of p73-dependent apoptosis through physical interaction and phosphorylation. J Biol Chem 283, 8555-63
18174154   Curated Info